Gastric Small Cell Carcinoma Successfully Treated by Surgery and Postoperative Chemotherapy Consisting of Cisplatin and S-1: Report of a Case

Koide, Naoki; Suzuki, Akira; Saito, Hiroyasu; Sato, Toshiyuki; Murakami, Maki; Ota, Hiroyoshi; Miyagawa, Shinichi

doi:10.1007/s00595-007-3504-x

Cited by 18 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we found no survival benefit of adjuvant chemotherapy for advanced gastric EC. Recently, some authors have reported successfully treating cases of gastric EC with different combination chemotherapies, such as etoposide/CDDP, CPT-11/CDDP, and S-1/CDDP [19,22,[24][25][26][27][28]. However, at present there is no standard chemotherapy regimen for advanced gastric EC.…”

Section: Discussionmentioning

confidence: 99%

Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute

et al. 2012

View full text Add to dashboard Cite

Background Gastric endocrine carcinoma (EC) is an uncommon tumor of the stomach and the clinical features are not well known. Additionally, the classification and staging systems of this tumor are not yet unified worldwide. In this study, we reviewed 27 patients with gastric EC to evaluate the clinicopathological characteristics of this tumor. Methods We retrospectively reviewed 27 patients with gastric EC among 6466 patients who had undergone gastrectomy between 1986 and 2008 at our institute. Clinicopathological features including immunohistochemistry of Ki-67 were investigated to evaluate the malignant potential of the tumor. Furthermore, survivals were compared between the 7th edition of the International Union Against Cancer (UICC)-TNM (7th TNM) classification for gastric cancer (GC) and the new TNM classification for foregut neuroendocrine tumors (NET). Results The median survival of the patients was 19.0 months. The 5-year survival rate was 100% in pathological stage (pStage) I, 40% in pStage II, 38% in pStage III, and 11% in pStage IV according to the 7th TNM classification for GC. Survivals by stage showed great difference between the 7th TNM classification for GC and the new TNM classification for foregut NET, but each system correlated with survival. The Ki-67 labeling index was more than 20% in most of the patients. Univariate analysis revealed that maximum tumor diameter, tumor depth, lymph node metastasis, lymphatic invasion, pStage, and curability had significant correlations with survival. Conclusion Early detection and curative operations are essential for improving the prognosis of gastric EC. However, some adjuvant chemotherapies are required for advanced-stage tumors. Classification and staging systems may need to be unified worldwide for further analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Recently, few studies have reported favorable results with a combined treatment modality of surgery followed by chemotherapy in resectable cases of GSCC, which are similar to that for conventional gastric cancer 2,9,10,11) . On the other hand, in unresectable cases, chemotherapy showed efficacy for GSCC 3,12,13,14,15) .…”

Section: Discussionmentioning

confidence: 85%

“…On the other hand, in unresectable cases, chemotherapy showed efficacy for GSCC 3,12,13,14,15) . Among the various regimens of chemotherapy reported, cisplatin has been frequently mentioned in the literature 2,3,9,10,11,12,14,15,16) . It remains unclear whether chemotherapy should be given before or after surgery; however, it may be essential in the treatment of GSCC.…”

Section: Discussionmentioning

confidence: 99%

Gastric Small Cell Carcinoma That Showed Complete Response to Irinotecan+Cisplatin Chemotherapy Treatment –A Case Report–

Tsukada

Tauchi

Nakamura

et al. 2011

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

Generally, clinical outcome of gastric small cell carcinoma is extremely poor. In this paper, we report a case of a patient with gastric small cell carcinoma who completely responded to chemotherapy and showed a long survival without recurrence. A 56-year-old man was admitted to our hospital with symptoms of weight loss and a large mass in the upper abdomen. Esophagogastroduodenoscopy revealed a large tumor located in the posterior wall of the antrum of the stomach. Computed tomography revealed a large mass involving the stomach with regional lymph node metastasis and direct pancreatic invasion. Pathological and immunohistochemical analyses indicated a diagnosis of primary gastric small cell carcinoma. Curative resection was not considered likely, and hence, a combination chemotherapy consisting of irinotecan and cisplatin was administered. Following 4 cycles of chemotherapy, complete remission was confirmed. The treatment was stopped after 9 cycles as per the patient's request. The patient survived for more than 8 year without recurrence since the first diagnosis of cancer. This case suggests that combination chemotherapy with irinotecan and cisplatin, which is recognized as one of the standard regimens for small cell carcinoma of the lung, can provide clinical benefits for patients with gastric small cell carcinoma.

show abstract

“…A response rate of 41.5% [9] and median sur vival range of 10.4 mo have been reported [10] . In another report, four of 11 patients with endocrine cell carcinomas who were treated with S-1 survived for over 2 years after surgery [11,12] .…”

Section: Issnmentioning

confidence: 99%

A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism

Tanoue¹,

Tanaka²,

Suzuki³

et al. 2009

WJG

View full text Add to dashboard Cite

We report a case of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein (IMV) tumor embolism. A 79-year-old woman was admitted to our hospital with narrowing of the stools. We performed colonoscopy, computed tomography and positron emission tomography, which disclosed sigmoid colon cancer with IMV tumor embolism. She underwent sigmoidectomy and lymph node dissection. The tumor was diagnosed as endocrine cell carcinoma (type 4, pSS, med, INFa, v3, n1, stage Ⅲb). Immunohistochemically, chromographin A, synaptophysin, cytokeratin 20 and mucicarmine showed partial staining, and CD56 was totally reactive. Three months after operation multiple liver metastases appeared. She was treated with chemotherapy of cisplatin (CDDP) + irinotecan (CPT11). This case highlights the aggressiveness of endocrine cell carcinoma with tumor embolism, and it is essential to establish an accurate diagnosis and effective treatment.

show abstract

Gastric Small Cell Carcinoma Successfully Treated by Surgery and Postoperative Chemotherapy Consisting of Cisplatin and S-1: Report of a Case

Cited by 18 publications

References 13 publications

Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute

Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute

Gastric Small Cell Carcinoma That Showed Complete Response to Irinotecan+Cisplatin Chemotherapy Treatment –A Case Report–

A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism

Contact Info

Product

Resources

About